A carregar...
The Approval Process for Biosimilar Erythropoiesis-Stimulating Agents
A biosimilar drug or follow-on biologic drug is defined by the Public Health Service Act as a product that is “highly similar to the reference product notwithstanding minor differences in clinically active components and there are no clinically meaningful differences between the biologic product and...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
American Society of Nephrology
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4152809/ https://ncbi.nlm.nih.gov/pubmed/24970875 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.01770214 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|